A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma

Ghassan K Abou-Alfa, Rebecca A Miksad, Mohamedtaki A Tejani, Stephen Williamson, Martin E Gutierrez, Olugbenga O Olowokure, Manish R Sharma, Imane El Dika, Matthew L Sherman, Shuchi S Pandya, Ghassan K Abou-Alfa, Rebecca A Miksad, Mohamedtaki A Tejani, Stephen Williamson, Martin E Gutierrez, Olugbenga O Olowokure, Manish R Sharma, Imane El Dika, Matthew L Sherman, Shuchi S Pandya

Abstract

Lessons learned: Patients with hepatocellular carcinoma (HCC) often have limited therapeutic responses to the vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor sorafenib, which is standard of care in advanced HCC. Targeting the activin receptor-like kinase 1 (ALK1) and VEGF pathways simultaneously by combining the ALK1 ligand trap dalantercept with sorafenib may result in more effective angiogenic blockade and delay tumor progression in patients with advanced HCC.Although the combination was generally well tolerated, there was no additive antitumor activity with the combination of dalantercept plus sorafenib in patients with advanced HCC. No complete or partial responses were observed, and overall survival ranged from 1.9 to 23.3 months.These results suggest that, in this patient population, further development of the possible limited benefits of combination therapy with dalantercept plus sorafenib is not warranted.

Background: Targeting the activin receptor-like kinase 1 (ALK1) and vascular endothelial growth factor (VEGF) pathways may result in more effective angiogenic blockade in patients with hepatocellular carcinoma (HCC).

Methods: In this phase Ib study, patients with advanced HCC were enrolled to dose-escalation cohorts, starting at 0.6 mg/kg dalantercept subcutaneously every 3 weeks plus 400 mg sorafenib orally once daily, or to a dose expansion cohort. The primary objective was to determine the safety and tolerability and the dalantercept maximum tolerated dose (MTD) level. Secondary objectives were to assess the preliminary activity and the association of pharmacodynamic biomarkers with tumor response.

Results: A total of 21 patients were enrolled in the study. Five patients received 0.6 mg/kg dalantercept in the first dose escalation cohort. Based on the initial safety results, the dose level was de-escalated to 0.4 mg/kg in the second cohort (n = 6). The MTD was identified as 0.4 mg/kg and used for the dose expansion cohort (n = 10). At this dose level, the combination was generally well tolerated. Overall survival ranged from 1.9 to 23.3 months, and the best overall response was stable disease.

Conclusion: The addition of dalantercept to sorafenib did not improve antitumor activity in patients with HCC. The dalantercept program in this population was discontinued.

Trial registration: ClinicalTrials.gov NCT02024087.

© AlphaMed Press; the data published online to support this summary is the property of the authors.

Figures

Figure 1.
Figure 1.
Study design and patient disposition.Abbreviations: Q3W, every 3 weeks; QD, once daily.

References

    1. Townson S, Martinez‐Hackert E, Greppi C et al. Specificity and structure of a high affinity activin receptor‐like kinase 1 (ALK1) signaling complex. J Biol Chem 2012;287:27313–27325.
    1. Brown MA, Zhao Q, Baker KA et al. Crystal structure of BMP‐9 and functional interactions with pro‐region and receptors. J Biol Chem 2005;280:25111–25118.
    1. Wang X, Solban N, Khanna P et al. Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma. Oncotarget 2016;7:41857–41869.
    1. Voss M, Bhatt R, Plimack E et al. The DART study: Results from the dose‐escalation and expansion cohorts evaluating the combination of dalantercept plus axitinib in advanced renal cell carcinoma. Clin Cancer Res 2017;23:3557–3565.
    1. Jimeno A, Posner MR, Wirth LJ et al. A phase 2 study of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck. Cancer 2016;122:3641–3649.
    1. Makker V, Filiaci VL, Chem LM et al. Phase II evaluation of dalantercept, a soluble recombinant activin receptor‐like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: An NRG oncology/gynecologic oncology group study 0229N. Gynecol Oncol 2015;138:24–29.
    1. Bendell J, Gordon M, Hurwitz H et al. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor‐like kinase‐1 ligand trap, in patients with advanced cancer. Clin Cancer Res 2014;20:480–489.
    1. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
    1. Seki T, Yun J, Oh SP. Arterial endothelium‐specific activin receptor‐like kinase 1 expression suggests its role in arterialization and vascular remodeling. Circ Res 2003;93:682–689.
    1. Shi Y, Massague J. Mechanisms of TGF‐beta signaling from cell membrane to the nucleus. Cell 2003;113:685–700.
    1. Oh S, Seki T, Goss K et al. Activin receptor‐like kinase 1 modulates transforming growth factor‐beta 1 signaling in the regulation of angiogenesis. Proc Natl Acad Sci U S A 2000;97:2626–2631.
    1. Mitchell D, Pobre E, Mullvor A et al. ALK1‐Fc inhibits multiple mediators of angiogenesis and suppresses tumor growth. Mol Cancer Ther 2010;9:379–388.
    1. Hu‐Lowe D, Chen E, Zhang L et al. Targeting activin receptor‐like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti‐VEGF therapies. Cancer Res 2011;71:1362–1273.
    1. Cunha SI, Pardali E, Thorikay M et al. Genetic and pharmacological targeting of activin receptor‐like kinase 1 impairs tumor growth and angiogenesis. J Exp Med 2010;207:85–100.
    1. Cunha S, Pietras K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011;117:6999–7006.
    1. The Human Protein Atlas . ACVRL1. Available at . Accessed January 25, 2018.
    1. Li Q, Gu X, Weng H et al. Bone morphogenetic protein‐9 induces epithelial to mesenchymal transition in hepatocellular carcinoma cells. Cancer Sci 2013;104:398–408.
    1. Roodhart JM, Langenberg MH, Witteveen E et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008;3:132–143.
    1. Niessen K, Zhang G, Ridgway JB et al. ALK1 signaling regulates early postnatal lymphatic vessel development. Blood 2010:115:1654–1661.
    1. Duong T, Koopman P, Francois M. Tumor lymphangiogenesis as a potential therapeutic target. J Oncol 2012;2012:204946–204969.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅